Antithrombotic treatment from the point of view of new guidelines for the management of atrial fibrillation

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F11%3A%230000185" target="_blank" >RIV/00098892:_____/11:#0000185 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

čeština

Original language name

Antitrombotická léčba z pohledu nových doporučení pro léčbu nemocných s fibrilací síní

Original language description

Atrial fibrillation is associated with significantly greater rates of morbidity and mortality, caused primarily by thromboembolic complications. The prevention of thromboembolic strokes is therefore one of the most important elements of the complex treatment of atrial fibrillation. Different strategies for anticoagulant or antiplatelet therapy in patients with atrial fibrillation are recommended for the prevention of thromboembolic complications according to the presentation of a different number of risk factors. New guidelines optimize antithrombotic treatment according to new risk stratification (CHA2DS2Vasc score) and mentioned the future of alternative antithrombotic treatment using direct thrombin antagonists or factor Xa inhibitors.

Czech name

Antitrombotická léčba z pohledu nových doporučení pro léčbu nemocných s fibrilací síní

Czech description

Atrial fibrillation is associated with significantly greater rates of morbidity and mortality, caused primarily by thromboembolic complications. The prevention of thromboembolic strokes is therefore one of the most important elements of the complex treatment of atrial fibrillation. Different strategies for anticoagulant or antiplatelet therapy in patients with atrial fibrillation are recommended for the prevention of thromboembolic complications according to the presentation of a different number of risk factors. New guidelines optimize antithrombotic treatment according to new risk stratification (CHA2DS2Vasc score) and mentioned the future of alternative antithrombotic treatment using direct thrombin antagonists or factor Xa inhibitors.

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FA - Cardiovascular diseases including cardio-surgery

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2011

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Kardiologická revue

ISSN

1212-4540

e-ISSN

—

Volume of the periodical

13

Issue of the periodical within the volume

3

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

7

Pages from-to

153-159

UT code for WoS article

—

EID of the result in the Scopus database

—